Appendix 4D and Half Year Financial Report
Filed with ASX · · 20 pages · English
Summary by 6ix AI
The report indicates a significant decline in revenues from ordinary activities and an increase in losses attributable to the owners of the company compared to the previous period. Operating expenses rose due to heightened clinical trial activities and share-based payment expenses during the half-year. The company reported no dividends paid or declared during this financial period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- December 2025 Quarterly Update and Appendix 4C
- PTX secures EU Authorisation to commence PTX-100 Trial
- PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
- September Quarterly Updated and Appendix 4C
- Appendix 4E and 2025 Annual Report
Later from Prescient Therapeutics
- March 2026 Quarterly Update and Appendix 4C
- June 2026 Quarterly Update and Appendix 4C
- Appendix 4G and Corporate Governance Statement
- Appendix 4E and 2026 Annual Report
- Prescient Therapeutics Launches Share Purchase Plan for $7m
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics